Although the incidence of malaria has declined in all but a few countries worldwide, according to a World Health Organization report earlier this month, malaria remains a global threat. Nearly 800,000 people succumbed to the mosquito-borne disease in 2009, nearly all of them in the developing world.

Physicians do not have reliable treatment for the virus at various stages, largely because no one has been able to document the malaria parasite’s journeys in the body.

Now researchers at Brown University and the Massachusetts Institute of Technology have used advanced computer modeling and laboratory experiments to show how malaria parasites change red blood cells and how the infected cells impede blood flow to the brain and other critical organs.

Their findings, published in the early online edition of the Proceedings of the National Academy of Sciences, could help doctors chart, in real time, the buildup in the body of cells infected with malaria or other diseases (such as sickle-cell anemia) and to prescribe treatment accordingly.

“The idea is to predict the evolution of these diseases, just like we predict the weather,” said George Karniadakis, professor of applied mathematics at Brown and corresponding author on the paper.

The researchers worked with Plasmodium falciparum, a parasite that can cause cerebral malaria by lodging in capillaries of the brain, especially among children. The parasite is found globally but is most common in Africa.

Once introduced into the human body by an infected mosquito’s bite, the parasite invades red blood cells. Healthy red blood cells are tremendously elastic; even though they can reach 8 microns in length and 2 microns in thickness, they can easily slide through a capillary just 3 microns in diameter. Capillaries are vital conduits in the human brain and other organs; red blood cells are key transporters of oxygen and nutrients.

Through extensive modeling carried out on one of the world’s fastest supercomputers at the National Institute for Computational Sciences, Karniadakis and colleagues found that malaria-infected red blood cells stiffened as much as 50 times more than healthy red blood cells. The result: Infected red blood cells, having lost their elasticity, could no longer pass through capillaries, effectively blocking them.

“Basically what happens is the brain could be deprived of nutrients and oxygen,” said Karniadakis, a member of the Center for Fluid Dynamics, Turbulence and Computation at Brown. “This happens because of the deformation of these red blood cells.

“This shows that as stiffening increases (in red blood cells), the viscosity of the blood increases, and the heart has to pump twice as much sometimes to get the same blood flow,” Karniadakis added.

The researchers also found that infected red blood cells had a tendency to stick, flip, and flop along the walls of blood vessels – unlike healthy blood cells that flow in the middle of the channel. For reasons not entirely known, the infected red blood cells develop little knobby protrusions on their cellular skin that tend to stick to the surface of the blood wall, known as the endothelium. Scientists call the sticking cytoadhesion.

“So, what happens is the infected red blood cell is not only stiffer, it’s slowed down by this interaction (cytoadhesion),” Karniadakis said. “This drastically changes the flow of blood in the brain, especially in the arterials and in the capillaries.”

Notes:

Dimitry Fedosov, first author on the paper, worked on the research as a graduate student at Brown. He is now a postdoctoral researcher at the Institute of Solid State Research in Germany. Bruce Caswell, professor emeritus in the School of Engineering at Brown, contributed to the research. Subra Suresh, former dean of the engineering school at MIT and now director of the National Science Foundation, also contributed to the research.

The National Institutes of Health and the NSF funded the research.

Source:
Richard Lewis
Brown University

A Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease has been established by Vanderbilt University Medical Center and Meharry Medical College. The Center will seek to bring high quality care to people with sickle cell disease (SCD) that is seamless and lifelong.

Michael DeBaun, M.D., MPH, an internationally renowned researcher in the area of SCD, has been named director of the new Center for Excellence. DeBaun, recently named vice chair for Clinical Affairs for the Vanderbilt Department of Pediatrics, arrives at Vanderbilt in November from Washington University in St. Louis.

DeBaun says he envisions teams of specialists from Vanderbilt and Meharry working shoulder to shoulder with community physicians to care for those with sickle cell disease. He also envisions family-centered care, and active involvement of the community within the Center.

“What attracted me to Vanderbilt was a willingness to embrace a model for care where individuals with sickle cell disease would have a permanent medical home across the life spectrum. The primary goal for the center is delivering the highest quality of care to improve the lives of infants, children and adults with sickle cell disease and their families,” DeBaun said.

Sickle cell disease is one of the most common genetic diseases in the United States, occurring in one in 400 births in African-Americans. The disease affects the red blood cells, causing the cells to become permanently deformed with an appearance of a sickle, interrupting the flow of blood in the smallest of blood vessels. Approximately 100,000 individuals in the United States have SCD and are at risk for chronic disease including heart, lung and strokes as a result of the disease.

DeBaun says care for individuals with sickle cell disease has historically been fragmented. Those with SCD have a difficult time coordinating between different specialists and their primary care provider, especially after childhood when many patients lose their primary care provider because they lose their health insurance.

“When a patient has a chronic health condition, we have to work harder to ensure they have a medical home, particularly when they become young adults,” DeBaun said.

Meharry and Vanderbilt currently provide many specialized services to people with sickle cell anemia; notably Vanderbilt’s transition clinic for teens moving to adult care and Meharry’s work as the primary testing center for the Middle Tennessee area. Both academic medical centers provide ongoing clinical care as well as genetic testing and research in the area of Sickle Cell Disease.

Charles P. Mouton, M.D., M.S., Senior Vice President for Health Affairs and Dean of the Meharry School of Medicine, says the recruitment of DeBaun to Vanderbilt opens up a new chapter in Meharry’s fight against sickle cell disease.

“With a strong track record of experience and community engagement throughout his career, Dr. DeBaun provides us with another partner to more fully engage in battling the problem of sickle cell disease. We hope that through this new partnership with Vanderbilt and helping to strengthen the relationships with the community, we will be able to fully address the problem of sickle cell disease in Middle Tennessee,” Mouton said.

Debra L. Friedman, M.D., E. Bronson Ingram Chair in Pediatric Oncology and director of Pediatric Hematology-Oncology, says the Sickle Cell Center of Excellence will transform the care of patients with SCD in the region.

“The research projects Dr. DeBaun leads will bring clinical care of sickle cell disease to a new level, but one of the most exciting things about Dr. DeBaun is his passion for developing novel health care models for this population,” Friedman said.

When DeBaun arrives in November, he will bring with him the clinical coordinating center for the National Institutes of Health (NIH) Silent Cerebral Infarct Transfusion Trial. A second NIH study provides collaboration nationally and internationally to develop the first longitudinal cohort of children with sickle cell anemia evaluated with repeated pulmonary function tests and sleep studies.

Source:

Vanderbilt University Medical Center

EBMT, the European Group for Blood and Marrow Transplantation, is pleased to announce its 35th Annual Congress in Gothenburg, Sweden, from 29th March to 1st April. This meeting is a forum to promote all activity aimed at improving stem cell transplantation (SCT) and cellular therapy. The meeting fosters exchange of the latest scientific findings between researchers, physicians, nurses, and data managers, as well as provides a forum for families, patients and others to meet, network, and exchange their experiences related to SCT and cellular therapy.

The congress has been carefully prepared to offer a scientifically stimulating and highly informative meeting. The Scientific Programme encompasses symposia, educational sessions and workshops covering issues related to the specific problems of stem cell transplantation in clinical practice, indications for transplantation, as well as basic and translational science relevant to the field. The sessions will be led by experts in the field of blood and marrow transplantation.

This year, the two plenary sessions focus on the cutting edge topics of the use of stem cells in the field of Regenerative Medicine – presented in three exciting talks on how stem cells can be used for organ repair – and on Immune Regeneration and Infection, which will address one of the historical limitations of stem cell transplantation and how knowledge about the regeneration of the immune system can help combat the threat of infection. The latest findings in the use of cord blood in the treatments of haematological malignancies will also be an important part of the programme. All of these issues will be discussed taking into account the paediatric perspectives.

The 25th Meeting of the EBMT Nurses Group

The topic this year is “Quality of life lessons – into the future”. Physicians and nurses will discuss the late effects of Bone Marrow Transplantations on sexuality and quality of life.

The 3rd EBMT Patient & Family Day

The third EBMT Patient & Family Day will take place in Gothenburg on Saturday 28th March. This event is now an established and integral part of the annual EBMT meeting and takes place the day before the scientific meeting each year. It is a unique opportunity for patients to share their experience. The programme will consist of three presentations, three plenary sessions and four workshops led by physicians, nurses and patients. The morning programme addresses important questions regarding the integrity of the sibling stem cell donors, and the problems that may occur when two family members meet the challenge of a stem cell transplantation; one as a patient and one as a potential donor. The second plenary session discusses the consequences of a cancer diagnosis for the patient’s body image, and the frequently overlooked problem of genital chronic Graft-versus-Host disease. In the afternoon, popular science lectures will be given on news and developments in the field of transplantation for leukemias, lymphomas and multiple myeloma.

For more information on the Congress and to see the full schedule, please visit
congrex.ch/ebmt2009

About the European Group for Blood and Marrow Transplantation

Bone marrow or stem cell transplantation is often the only curative treatment for different malignant
diseases and is currently performed on more than 50,000 patients worldwide each year. The
European Group for Blood and Marrow Transplantation (EBMT) as the leading non-profit, scientific
society representing 527 transplant centres in and outside Europe, promotes all activity aiming to
improve stem cell transplantation or cellular therapy. This includes registering all the activity relating
to stem cell transplants with a view to improving treatment outcomes for patients. EBMT has set
standards for indication and treatment for malignant and non-malignant diseases, along with running
training programmes for continual professional development. These are continually audited and
updated. EBMT is also responsible for accrediting the transplant centres based on their performance
and data reporting.

Source
European Group for Blood and Marrow Transplantation

Cord Blood Registry (CBR), the global leader in the collection and preservation of newborn stem cells from umbilical cord blood, announced its support of legislation introduced yesterday by U.S. Representatives Ron Kind (D-WI), Wally Herger (R-CA), Artur Davis (D-AL), Bill Pascrell Jr. (D-NJ) and Mike Thompson (D-CA) entitled the “Family Cord Blood Banking Act.” This important legislation will amend the IRS Code to allow individuals and couples to use tax advantaged dollars to pay for umbilical cord blood banking services through flexible spending accounts (FSAs), health savings accounts (HSAs), health reimbursement arrangements (HRAs) or the medical expenses tax deduction.

Speaking about the bill’s introduction, Rep. Ron Kind, the legislation’s chief sponsor and a Member of the House Ways and Means Subcommittee on Health, said, “This legislation supports families that choose this potentially life-saving investment by providing tax incentives for these medical expenses.”

Cord blood stem cells have been used in more than 14,000 transplants worldwide during the last 20 years to treat more than 70 diseases in both adults and children and are now showing great promise for regenerative medicine applications, including treatment for type 1 diabetes, brain injury, cerebral palsy and hearing loss. For many families, cord blood banking is the best option for treating and curing disease; however, the cost of family umbilical cord blood banking ($2,000 the first year; $125 per year thereafter) can present a challenge for families on fixed incomes.

Current tax laws arbitrarily restrict how families can use tax advantaged dollars in FSAs, HSAs, HRAs, or through the medical expenses tax deduction. “Families may pay for over-the-counter cough syrups or heartburn pills using these dollars, but not cord blood banking services,” said David Zitlow, senior vice president of public affairs and communications at CBR. “These limitations are unfair and even unwise – families who opt to deposit into tax advantaged health accounts should have the discretion to spend those dollars as they see fit on qualified medical expenses.”

The legislation is also likely to speed important research using cord blood stem cells. “Research and clinical trials involving cord blood will require more children to have a source of their own cord blood stem cells available for transplant. Consequently, legislation that makes it easier for families to bank cord blood will definitely speed up the time table for life-saving research and will allow scientists to unlock the vast potential of these amazing cells on a much quicker basis,” said Dr. David Harris, Cord Blood Registry’s Scientific Director and a stem cell researcher at the University of Arizona.

“The Family Cord Blood Banking Act” is supported by the Coalition for Regenerative Stem Cell Medicine, which includes groups like the Brain Injury Association of America (BIAA), Association of Nurse Practitioners in Women’s Health, The Parents Guide to Cord Blood Foundation and a growing number of organizations, researchers, and disease advocacy groups dedicated to raising awareness and lowering financial barriers of access to cord blood stem cells.

About Cord Blood Registry

Cord Blood Registry(R) (CBR(R)) is the world’s largest stem cell bank, focused on the collection, processing and storage of newborn stem cells from umbilical cord blood and ensuring their viability for medical use. CBR is the most recommended family cord blood bank by obstetricians and was the first family bank accredited by AABB (formerly the American Association of Blood Banks). The company has been profitable and cash flow positive from operations on a cumulative basis since 1999. To date, CBR has processed and stored cord blood units for more than 260,000 newborns from around the world and has released more client cord blood units for specific therapeutic use than any other family cord blood bank. The company’s research and development efforts are focused on helping the world’s leading clinical researchers advance regenerative medical therapies using cord blood stem cells as well as enhancing its industry-leading technical innovations for stem cell collection, processing and storage that optimize quality and cell yield. For more information, visit CordBlood.

Cord Blood Registry
cordblood

The Multiple Myeloma
Research Consortium (MMRC) today announced its participation in a Phase II
study to determine the efficacy of LBH589 for the treatment of patients
with relapsed or refractory multiple myeloma. LBH589 is an orally
administered deacetylase inhibitor developed by Novartis Pharmaceuticals.

The MMRC is the only research model of its kind bringing together 13
leading academic institutions to accelerate the development of novel and
combination treatments for multiple myeloma, an incurable cancer of the
plasma cell. In addition to its most recent partnership with Novartis, the
MMRC is facilitating several other clinical trials, including a Phase I
study of NPI- 0052, a proteasome inhibitor, in collaboration with Nereus
Pharmaceuticals, and a Phase I study of perifosine, lenalidomide
(REVLIMID(R)), and dexamethasone in collaboration with Keryx
Biopharmaceuticals.

“Deacetylase inhibitors may represent a new treatment options for
cancer patients and the MMRC is proud to work with Novartis to advance this
important clinical program,” said Kathy Giusti, Founder and Chief Executive
Officer of the MMRC, as well as a myeloma patient. “This trial and the
others the MMRC is facilitating demonstrate the importance of novel
collaborations in bringing new treatments to patients.”

Named ALPHA-MM, this trial is a single arm, open label, multi-center
global study that will enroll 144 patients in the United States, Canada,
and Europe. MMRC Member Institutions that will enroll patients are
Dana-Farber Cancer Institute, City of Hope National Medical Center, Emory
University, Hackensack University Medical Center, Mayo Clinic, H. Lee
Moffitt Cancer Center & Research Institute, and Washington University.

This trial is open to patients with relapsed or refractory multiple
myeloma who have received at least two lines of therapy, and whose disease
progressed on their most recent therapy. Prior therapy must have included
bortezomib (VELCADE(R)) or lenalidomide.

LBH589 is part of a promising class of drugs called deacetylase
inhibitors or HDAC inhibitors, which may play an important role in helping
to slow or stop the growth of multiple myeloma cells. Preclinical
laboratory data suggests that LBH589 has significant activity against
multiple myeloma cells, including those that are resistant to conventional
therapies.

About the Multiple Myeloma Research Consortium (MMRC)

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit
organization that integrates leading academic institutions to accelerate
drug development in multiple myeloma. It is led from MMRC offices in
Norwalk, Conn., and comprises 13 member institutions: City of Hope,
Dana-Farber Cancer Institute, Emory University’s Winship Cancer Institute,
the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt
Cancer Center & Research Institute, Mayo Clinic, Ohio State University,
Roswell Park Cancer Institute, St. Vincent’s Comprehensive Cancer Center of
Saint Vincent Catholic Medical Centers of New York, University Health
Network (Princess Margaret Hospital), University of Chicago, University of
Michigan, and Washington University.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and
with the help of the scientific community. The MMRC is a sister
organization to the Multiple Myeloma Research Foundation (MMRF), the
world’s leading funder of multiple myeloma research. The MMRC is widely
recognized as an optimal research model to rapidly address critical
challenges in drug development and to explore opportunities in the today’s
most promising research areas — genomics, compound validation, and
clinical trials. The MMRC is the only consortium to join academic
institutions through membership agreements, customized IT systems, and an
integrated tissue bank. For more information, please visit
themmrc.

The Multiple Myeloma Research Consortium
themmrc

Massage offers both physical and psychological benefits and is used at Nationwide Children’s Hospital in many areas including Rehabilitation, Physical Medicine and in patients who have received organ transplants, just to name a few. Researchers at Nationwide Children’s recently published a study in the Journal of Pediatric Psychology that revealed the benefits of massage in reducing pain, anxiety and depression in children with Sickle Cell Disease.

Sickle Cell Disease is an inherited blood disorder that affects the red blood cells, causing the cells to become hard and pointed instead of soft and round. More than 70,000 Americans suffer from this genetic disorder and it is considered an international health problem.

Kathleen Lemanek, PhD, and Mark Ranalli, MD, conducted the first study that measured the effects of massage in children with Sickle Cell Disease in a home setting. Eighteen of patients’ parents were trained by massage therapists, while 16 participants were used as a control group. They found children in the experimental group were significantly less depressed, less anxious and suffered from less pain after receiving massages from their parents.

“It’s important to note that massage may not be right for all patients with Sickle Cell Disease or even patients who may suffer from chronic pain,” said Dr. Lemanek, pediatric psychologist at Nationwide Children’s Hospital. “You have to consider personal characteristic and comfort levels of both the parents and child first before determining if massage is right.”

“Massage is an inexpensive and easy way to manage pain, which is a big part of having Sickle Cell Disease ,” said Dr. Ranalli, attending physician in Hematology, Oncology and Bone Marrow Transplant at Nationwide Children’s and a faculty member at The Ohio State University College of Medicine. “Pain management for Sickle Cell Disease typically includes hydration, nonsteriodal anti-inflammatory drugs and narcotics. Massage as a pain management technique can relax the muscles, increase circulation and help medication take a more effective route.”

Researchers measured both the children and their parents’ anxiety levels throughout this study and were surprised to find that parents who gave massages to their children had significantly higher anxiety levels at the end of the study. The requirement to provide a nightly massage and the stress of managing symptoms at home may have temporarily increased parents’ anxiety. However, if benefits are experienced overtime with regular massages, caregivers may experience a sense of control in reducing pain, consequently lowering their anxiety.

“Even though parents’ anxiety levels were increased, parents from the study said they would continue to use massage as a pain management tool,” said Dr. Lemanek, who is also a faculty member at The Ohio State University College of Medicine. “When your kids are in pain, despite medication, and parents feel hopeless like they have exhausted all options, massage can help them feel in control of the disease. When your child looks at you in pain, massage gives you the opportunity to do something to actively try and help.”

Source: Nationwide Children’s Hospital

An Indiana University Melvin and Bren Simon Cancer Center doctor will soon lead a pack of bicyclists on a 235-mile journey to raise awareness of multiple myeloma.

Rafat Abonour, M.D., an oncologist and researcher at the IU Simon Cancer Center, and a group of cyclists will begin their ride at 8:15 a.m. Friday, Oct. 8, at the Cancer Center at Ball Memorial Hospital in Muncie.

For Dr. Abonour, this is the sixth consecutive year he has set out on his bike for Miles for Myeloma, an annual cycling tour of Indiana cities. Dr. Abonour’s Miles for Myeloma raises awareness and research funds for multiple myeloma (pronounced mahy-uh-loh-muh), an incurable blood cancer.

According to the American Cancer Society, about 20,180 new cases will be diagnosed in 2010 and about 10,650 deaths are expected this year. The five-year survival rate for multiple myeloma is around 35 percent, according to the American Cancer Society.

To date, Dr. Abonour has raised nearly $1.5 million for multiple myeloma research. All of the funds are used by researchers at the IU Simon Cancer Center.

Each year, Dr. Abonour takes on a grueling ride – and sometimes a bike ride coupled with a long-distance run – because he knows myeloma patients endure so much every day with their disease.

A person with myeloma, according to Dr. Abonour, is typically around 60 years old. The cancer accumulates in bone marrow, weakening the bones and causing osteoporosis, anemia and kidney failure. Myeloma also leaves people susceptible to infections because their immune system has been weakened.

“We have to do more for people diagnosed with myeloma,” he said. “It’s so disheartening that we can’t cure these people. I think the mission is to find out why we can’t cure them – and change that.”

Finish-line celebration is Oct. 9 in downtown Indy

From Muncie, Dr. Abonour and the other cyclists – many of whom are IU School of Medicine colleagues – will head to Fort Wayne and other Indiana cities and towns before ending with a finish-line celebration at 4:30 p.m. Saturday, Oct. 9, in front of University Place Hotel on the Indiana University-Purdue University Indianapolis campus. More than 300 myeloma patients and family members are expected to gather to watch the 235-mile trek end. All are welcome to attend.

Notes

Miles for Myeloma 2010: Ride for Research visits Muncie, Hartford City, Fort Wayne, Logansport, Delphi, Lafayette, Lebanon, and Indianapolis.

Past Miles for Myeloma events were:

2009 Miles for Myeloma: Trek for Treatment: 207 miles by bike from Evansville to Indianapolis

2008 Miles for Myeloma: The Bloomington Boomerang Part II: 60-mile run from Indianapolis to Bloomington and 60-mile bike ride from Bloomington to Indianapolis

2007 Miles for Myeloma: The Bloomington Boomerang Part I: 60-mile run from Indianapolis to Bloomington and 60-mile bike ride from Bloomington to Indianapolis

2006 Miles for Myeloma: The South Bend Tour: 40-mile run from Carmel to Kokomo and a 100-mile bike ride from Kokomo to South Bend

2005 Miles for Myeloma: The Fort Wayne Tour: 60-mile bike ride from Carmel to Marion and a 60-mile run from Marion to Fort Wayne

For more on the Adult Hematology & Hematologic Malignancies Program at the IU Simon Cancer Center, visit here.

Source:

IU School of Medicine

1. Patient-Physician “Connectedness” Affects Quality of Care

Health care in the United States is often fragmented and uncoordinated. It is common for patients to receive episodic care from different physicians. A new study in Annals of Internal Medicine, however, finds that patients who are connected to a specific primary care physician are more likely to receive guideline-consistent care than those who are connected to a practice but not a physician.

Researchers looked at 155,590 adults in a primary care network to determine which patients received most of their care from a specific physician, practice, or neither. They found that patients who were not connected to a particular physician were less likely to receive recommended care. In addition, these patients were less likely to complete recommended testing for preventive and chronic illness care.

“This study provides strong evidence for the value of having a regular doctor,” said Steven Atlas, M.D., Director of Primary Care Quality Improvement at Massachusetts General Hospital, and lead author of the study.

Researchers used the term “connectedness” to describe the closeness of the relationship between a patient and an individual physician. The researchers found that patients who were connected to a physician were more likely to have health insurance, speak English, and be non-Hispanic white. However, connectedness was associated with larger disparities in screening rates than was race or ethnicity.

“The process of establishing a strong relationship with a specific physician may represent an important key to understanding disparities in care,” said Dr. Atlas. “Greater insight into the role of patient- provider- or practice-level barriers to establishing a closely connected primary care relationship may lead to improved quality of care for vulnerable patients.”

But according to researchers, continuity of care is a shared responsibility between physicians and patients. Even if physicians or practices treated all patients similarly, patients vary in their ability and willingness to adhere to recommendations.

According to Dr. Atlas, this study has health care policy implications as well.

“Pay-for-performance initiatives hinge on the ability to accurately assign performance measures to those practitioners who have some control over the outcome. Our study results suggest that physicians with a relatively low percentage of connected patients are likely to receive lower scores on performance measures when compared to physicians with a higher proportion of connected patients,” said Dr. Atlas.

2. Black Patients Fare Worse than White Patients After Heart Attack: Risk Factors, Not Care, to Blame

Following a heart attack, black patients tend to do worse and are more likely to die than white patients. To find out what factors contribute to these differences in patient outcomes, researchers looked at 1,849 adults who had a heart attack and were hospitalized at one of 10 U.S. hospitals that participated in a registry of heart attack care. The registry included information about patients’ health and social factors. It also included information about death, rehospitalization, chest pain, and quality of life after heart attack. The researchers found that black and white patients who had similar severity of heart and other diseases and similar social factors, such as level of education, had similar heart attack outcomes. Researchers conclude that the differences in heart attack outcomes between black and white patients seem to be due to worse risk factors for heart disease in black patients rather than to differences in the care that patients receive. Strategies to reduce black-white differences in outcomes after heart attack should focus on improving heart risk factors in black patients.

3. Vitamin K Same as Placebo for Treating Effects of Warfarin Overdose

Doctors prescribe warfarin to treat or prevent blood clots. But an overdose of warfarin can thin the blood too much, causing a bleeding event. Vitamin K can rapidly reverse the effects of a warfarin overdose. However, it is not known how vitamin K affects patient outcomes. Researchers sought to determine if patients taking vitamin K have fewer bleeding events or greater risk of clots. They conducted a study of 712 people taking warfarin whose blood tests showed their blood was too thin. Patients stopped taking warfarin and were randomly assigned either a low dose of vitamin K or placebo over a 90-day period. Researchers found that Vitamin K rapidly reduced the effects of warfarin. However, there were no differences between groups in the number of participants with bleeding events, clots, or other complications. Researchers conclude that temporarily stopping warfarin may be all that is needed to treat the effects of too much warfarin.

Source: Angela Collom

American College of Physicians

View drug information on Warfarin Sodium tablets.

Biologists at UC San Diego have identified the specific region in vertebrates where adult blood stem cells arise during embryonic development.

Their discovery, which appears in a paper in this week’s early online edition of the journal Nature, is a critical first step for the development of safer and more effective stem cell therapies for patients with leukemia, multiple myeloma, anemia and a host of other diseases of the blood or bone marrow.

The researchers say their time-lapse imaging of the process, by which primitive embryonic tissues first produce the parent stem cells that produce all adult blood cells over the life of an individual, should help guide future efforts to repair and replace this cell population for therapeutic purposes.

Current transplantation therapies rely on the infusion of donor stem cells into a patient’s bone marrow to generate new, healthy blood cells without disease. But that procedure is often risky and can result in fatal complications, due in part to “graft-versus-host disease,” in which transplanted cells react against foreign tissues of the recipient. One means of circumventing this immune rejection problem would be to generate hematopoietic stem cells, or HSCs, using the patient’s own precursor cells. Such cells would be perfectly genetically matched, but in order to generate such cells, scientists must first understand the molecular processes that underlie specification of HSCs.

“If we could generate healthy HSCs from patients and transplant them back into their own bone marrow, it would eliminate many complications,” said David Traver, an assistant professor of biology who headed the research team.

“Our findings are an important step toward this goal because they provide a better understanding of how HSCs, the cell type responsible for the clinical benefits of bone marrow transplants, are first specified during development,” he said. “This improved understanding will aid efforts to instruct pluripotent embryonic stem cells (ESCs), the stem cells that can produce all types of tissue-specific stem cells in the body, to make HSCs; something that is not currently possible. In other words, we are one step closer now to understanding how to clinically generate HSCs for cellular replacement therapies from ESCs.”

Traver and his colleagues, who included Julien Bertrand, a postdoctoral fellow in his laboratory, Neil Chi, an assistant professor of medicine at UCSD and Didier Stainier, a professor of biochemistry at UC San Franscisco, made their discoveries in zebrafish, a model laboratory organism for geneticists in which embryos are transparent, allowing the researchers to observe and track individual stem cells with a microscope.

A number of earlier studies using indirect observation had led to the idea that a particular region of the embryo surrounding the dorsal aorta, an early blood vessel, produced the first HSCs, but until now no one had been able to directly visualize the process in living animals.

“Indeed a number of conflicting studies had proposed different or earlier sites of origin, making the exact location where HSCs develop controversial,” said Traver. “Using zebrafish embryos with fluorescently labeled tissues, we were able to demonstrate that HSCs arise directly from cells lining the floor of the dorsal aorta by imaging the process in living embryos.”

The UCSD researchers also documented the stepwise formation of HSCs from “hemogenic” aortic endothelium and showed, by expressing a permanent fluorescent marker in these cells, that all adult blood and immune cell types derive from aortic endothelium of the early embryo.

“Our studies suggest that transition through a hemogenic endothelial intermediate is a requisite step for hematopoietic stem cell formation,” said Traver. “Based upon the high degree of evolutionary similarity in the regulation of HSC formation and later blood maturation in other vertebrates, this finding almost certainly applies to the development of HSCs in humans. These findings should, together with recent breakthroughs in making induced pluripotent stem cells (iPSCs), the functional equivalent of patient-specific ESCs, in principle allow the generation of replacement HSCs from unrelated adult tissues. This would enable repopulation of a patient’s hematopoietic system with his own, disease-free HSCs to avoid immune rejection.”

Other researchers involved in the study included Buyung Santoso and Shutian Teng of UCSD. The study was supported by grants from the National Institutes of Health and the California Institute for Regenerative Medicine.

Source:
Kim McDonald
University of California – San Diego

NICE has today issued final guidance recommending azacitidine (Vidaza, Celgene) as a treatment option for people with myelodysplastic syndromes (MDS).

Azacitidine has been recommended in line with its licensed indications, which means that it is now a treatment option for patients that have one of the following conditions and who are not eligible for haematopoietic stem cell transplantation: intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia.

Dr Carole Longson, Health Technology Evaluation Centre Director at NICE said: “We are pleased to be able to recommend this new treatment for MDS – it is not a cure, but it has the potential to extend life expectancy for these patients. During consultation on the draft recommendations, the manufacture of azacitidine offered to provide the drug at a reduced price. Azacitidine is an expensive drug, and this discount enabled us to recommend it as a cost effective use of resources on the NHS.”

Myelodysplastic syndromes (MDS) are a group of bone marrow disorders, where the marrow doesn’t produce enough of one or more types of blood cells. The majority of patients with MDS receive best supportive care in current clinical practice, and some patients receive low-dose or standard-dose chemotherapy. There are approximately 700 patients in England and Wales with the type of MDS for which azacitidine is licensed.

Notes

About the appraisal

1. The guidance will be available from 23 March here.

2. Azacitidine is the first drug that has been developed specifically for treating myelodysplastic syndromes. It is not a cure, but it does have the potential to extend patients’ lives. The clinical trial reported an average life extension of nine months.

3. The Committee agreed that azacitidine met the criteria for being a life-extending, end-of-life treatment and considered that, on balance, the additional weight that would need to be assigned to the QALY benefits in this patient group for the cost effectiveness of azacitidine to fall within the current threshold range was acceptable.

4. The committee agreed that the most plausible ICER for azacitidine in the overall patient population was approximately £47,200 per QALY gained. This included the patient access scheme.

5. The Department of Health and the manufacturer have agreed that azacitidine will be available to the NHS with a patient access scheme in which a discount is applied to all invoices. The level of the discount is confidential. It is the responsibility of the manufacturer to communicate the level of discount to the relevant NHS organisations.

Source:

NICE

View drug information on Vidaza.

Tag Cloud